Pleural Medicine Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, Avda Alcalde Rovira Roure 80, 25198, Lleida, Spain.
Institute for Biomedical Research Dr Pifarre Foundation, IRBLLEIDA, Lleida, Spain.
Lung. 2017 Dec;195(6):775-779. doi: 10.1007/s00408-017-0050-1. Epub 2017 Sep 12.
Malignant pleural effusions (MPE) may either coincide with or follow the diagnosis of a primary tumor. Whether this circumstance influences prognosis has not been well substantiated.
Retrospective review of all consecutive patients who were cared for at a Spanish university hospital during an 11-year period and received a diagnosis of MPE.
Of 401 patients, the MPE was the first evidence of cancer in 265 (66%), and it followed a previously diagnosed neoplasm in 136 (34%). Lung cancer predominated in the former group (131, 50%), and breast cancer in the latter (55, 40%). MPE that were the presenting manifestation of hematological and ovarian tumors had a statistically significant survival advantage as compared to those which developed in patients from a previously known cancer (respective absolute differences of 41 and 20 months; p < 0.005).
In hematological and ovarian malignancies, the synchronous or metachronous diagnosis of MPE may have prognostic implications.
恶性胸腔积液（MPE）可能与原发性肿瘤同时发生，也可能在其之后发生。这种情况是否会影响预后尚未得到充分证实。
回顾性分析了在西班牙一家大学医院接受治疗的 11 年间连续收治的所有患者的资料，这些患者均被诊断为 MPE。
401 例患者中，265 例（66%）MPE 是癌症的首发表现，136 例（34%）MPE 是在先前诊断的肿瘤之后发生的。前者以肺癌为主（131 例，50%），后者以乳腺癌为主（55 例，40%）。与先前已知癌症患者发生的 MPE 相比，血液系统和卵巢肿瘤的首发 MPE 具有统计学显著的生存优势（分别为 41 个月和 20 个月的绝对差异；p < 0.005）。
在血液系统和卵巢恶性肿瘤中，MPE 的同步或异时诊断可能具有预后意义。
